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Five (15.5%) of the 33 pregnant
women had P. jiroveci DNA in their
nasal swab samples versus none (0%)
of the 28 nonpregnant controls
(p=0.04 by 1-sided Fisher exact test).
Immunologic parameters were not
tested. The P. jiroveci–positive
women were all multiparous with 1
(n=2), 2 (n=2), or 3 (n=1) previous
pregnancies.
These results suggest that pregnan-
cy is a host factor that favors asymp-
tomatic nasal carriage of P. jirovec.
However, PCR detection of P. jiroveci
DNA in the nares of pregnant women
does not necessarily indicate either a
mild active pulmonary infection or
viable or transmissible organisms. In
animal models, detection of P. carinii
DNA in nasal and oral samples is a
good indicator that Pneumocystis is in
the lungs (8).
These results also support the
hypothesis that pregnant women who
nasally carry P. jiroveci may play a
role as contagious sources for suscep-
tible persons, especially their
immunologically naive newborn
infants. This hypothesis warrants fur-
ther study. Mother-to-infant transmis-
sion may explain the accumulating
evidence that the primary infection is
widely acquired very early in life (9).
Recent animal model studies have
documented the early acquisition of P.
carinii (within 1 to 2 h after birth) in
neonatal rats, likely transmitted by the
dams (10). Evidence of mother-off-
spring transmission would be clinical-
ly relevant for infants born to HIV-
infected mothers, who currently rely
on empiric anti-Pneumocystis chemo-
therapy started at 1 month of age as
their only prophylactic option.
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First Evidence of
Aedes albopictus
(Skuse) in Southern
Chiapas, Mexico
To the Editor: The mosquito
Aedes albopictus (Skuse, 1894) was
first identified in the Americas in
Texas in 1985 (1,2). That year, this
newly introduced species had dis-
persed widely in Texas and was impli-
cated in the transmission of dengue
virus (3). Later, the first states in
Mexico that were infested by Ae.
albopictus were along the northern
Mexican border: Coahuila, Nuevo
Leon, and Tamaulipas (4,5; J.P.
Martínez-Muñoz, thesis). In 1997,
this species was reported farther south
in Veracruz (6). Although Ae. albopic-
tus was expected to spread to south-
ernmost Mexico, this mosquito has
never been reported there until now.
We have confirmed Ae. albopictus in
the city limits of Tapachula, southern
Chiapas, Mexico. 
On September 13, 2002, one of the
authors, who resides in Tapachula,
was bitten by a mosquito. He collect-
ed the specimen, which was later
identified as Ae. albopictus by the
Centro de Investigación de Paludismo
(CIP). Nearby larval habitats were
then comprehensively searched to
collect the immature stages of the
species; the sampling area was locat-
ed at 14° 55' 22.5'' north and 92°15'
05.7'' west at an altitude of 220 m
along the periphery of Tapachula. We
found the following containers with
larval stages of mosquitos: five water
containers, two discarded tires (con-Emerging Infectious Diseases • Vol. 9, No. 5, May 2003 607
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taining 300–3,000 mL of water), one
thermal bottle (250 mL), one plastic
bottle (50 mL), and one bucket (2,500
mL). Larvae were placed in plastic
bags and transported to CIP laborato-
ries, where they were allowed to
emerge to adults during 17 days. The
fourth instar larval and pupal exuvias
were fixed and identified to species
according to Darsie (7) and
Superintendência de Campanhas de
Saúde Pública (8). Twenty-five
female and male Ae. albopictus from
these collections are available from
CIP laboratory upon request. 
Additional field collections are
being conducted to establish the dis-
tribution range of this species along
the Chiapas coastal plain, to determi-
nate the entomologic levels of infesta-
tion, and to determine its susceptibili-
ty to insecticides. Considering the epi-
demiologic relevance of this discov-
ery, we have notified the proper health
authorities to take necessary control
measures to reduce the possibility of
increased dengue transmission and to
prevent other arboviruses, such as
West Nile virus (9), from being spread
by this new species in southern
Mexico. 
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and José Luis Torres-Estrada*
*Centro de Investigación de Paludismo/
Instituto Nacional de Salud Pública,
Chiapas, México
References
1. Centers for Disease Control. Aedes albopic-
tus introduction—Texas. MMWR Morb
Mortal Wkly Rep 1986;35:141–2. 
2. Centers for Disease Control. Aedes albopic-
tus infestation—United States, Brazil.
MMWR Morb Mortal Wkly Rep
1986;35:493–5. 
3. Moore CG, Francy DB, Eliason DA,
Monath TP. Aedes albopictus in the United
States: rapid spread of a potential disease
vector. J Am Mosq Control Assoc
1988;4:356–61. 
4. Ibáñez-Bernal S, Martínez-Campos C.
Aedes albopictus in México. J Am Mosq
Control Assoc 1994;10:231–2. 
5. Rodríguez-Tovar ML, Ortega-Martínez
MG.  Aedes albopictus in Muzquiz City,
Coahuila, México. J Am Mosq Control
Assoc 1994;10:587. 
6. Secretaría de Salud. 2000. Available from:
URL: http://www.ssaver.gob.mx/Servicios
_de_Salud/BoletinEpidem/ Boletines/2000-
6/ page17.html 
7. Darsie RF Jr. The identification of Aedes
albopictus in the neartic region. J Am Mosq
Control Assoc 1986;2:336–40. 
8. Superintendência de Campanhas de Saúde
Pública. Resumo dos principias caracteres
morfológicos diferenciais do Aedes aegypti
e do Aedes albopictus. Brasilia: SUCAM/
Min. da Saúde; 1989. 
9. Holick J, Kyle A, Ferraro W, Delaney RR,
Iwaseczk M. Discovery ofAedes albopictus
infected with West Nile virus in southeast-
ern Pennsylvania. J Am Mosq Control
Assoc 2002;18:131. 
Address for correspondence: Mauricio Casas-
Martínez, Centro de Investigación de
Paludismo, Instituto Nacional de Salud Pública,
Apartado Postal 537, Tapachula, Chiapas, C. P.
30700, México; fax: (962) 626 57 82; email:
mcasas@insp.mx
Virus Isolation and
“Acute” West Nile
Virus Encephalitis
(Response to
Huang et al.)
To the Editor: We read with inter-
est a recent article in your journal,
First Isolation of West Nile virus from
a Patient with Encephalitis in the
United States (1); in the report, we
were unable to ascertain indisputable
evidence that this patient had indeed
acquired acute West Nile virus
(WNV) encephalitis. In animals (2,3)
and humans (4), West Nile virus can
persist in the host even after the host
has recovered from an acute WNV
infection, presumably more so in the
immunocompromised persons. There-
fore, in the case described by Huang
et al. (1), proving that the patient did
not have a history of WNV infection
is important, particularly because this
patient is from a geographic area
where WNV is known to exist. The
findings at autopsy of perivascular
lymphocyte cuffing in mammillary
bodies of the brain are not the classic
findings reported during the West Nile
encephalitis outbreak in New York
City (5). The immunoglobulin (Ig) G
antibody against WNV, if it had been
present, would have been useful in
that IgG antibody in the absence of
IgM antibody is indicative of past
rather than acute infection.
The WNV copy numbers in clini-
cal samples and clinical indices
(leukocyte count) suggest that the
virus multiplies in the setting of
leukopoenia or immune suppression
and cannot be definitive proof that it
was an acute infection, unless a nega-
tive preillness sample was available.
The cause of the transient viremia,
whether acutely acquired or from
increased proliferation in a chronic
infection, needs to be clarified fur-
ther. In the future, antigen detection
will guide patient management deci-
sions; therefore, the possibility of a
human chronic carrier state warrants
study. 
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